PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant

NCT01685359 | Completed Phase 1 DMC

• 2 other identifiers: EPOBLA0612IV-I2Version 1 25/06/2012
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The hypothesis of this trial is that the test drug (Human Recombiant Epoetin - Blau) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ® - Janssen-Cilag) in healthy subjects following administration of multiple intravenous dose. The objective of this randomized, parallel, clinical trial is to evaluate the pharmacokinetic and pharmacodynamic profile of the test drug Human Reconbiant Epoetin produced by Blau Farmacêutica, compared to the comparator drug Eprex®, produced by Janssen-Cilag, by assessing plasma concentration of the drug and the reticulocyte count following a multiple intravenous administration during 4 weeks of 100 IU/kg in healthy subjects.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• rHuEPO Serum Concentration

  Time frame on days 1, 8, 19 and 22: -10min, 0h, 5min, 15min, 30min, 45min, 1,5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h and 12h after administration; Time frame on day 26: -10min, 0h, 5min, 15min, 30min, 45min, 1,5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h and 36h after last drug administration.

  1, 8, 15, 19, 22 and 26 days after first administration

• Plasma reticulocyte count

  Time frame on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26: 10 minutes before drug administration. Time frameon day 29: 72h +/- 2h after last drug administration.

  1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 and 29 days after first administration of the drug.

Study Arms (2)

Test Drug

EXPERIMENTAL

Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration

Drug: Epoetin Alfa

Eprex

ACTIVE COMPARATOR

Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration

Drug: Epoetin Alfa

Interventions

Epoetin Alfa DRUG

Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)

Also known as: Eprex

Eprex; Test Drug

Eligibility Criteria

• Age: 20 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Agree to all the purposes of the study by signing and dating the Informed Consent;
• Male, aged between 20 and 55 years, clinically healthy;
• BMI between 18.5 and 30;
• Hemoglobin between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;
• VCM between 82 and 98, HBMC between 26 and 34, platelets between 150,000 and 400,000 units per mL. and WBC between 3,500 to 10,500 units per ml and no atypical cells.
• Human serum ferritin between 36-262 mcg / L;
• Counting of reticulocytes in peripheral blood ≤ 3%;
• Serum erythropoietin \< 30 mIU / mL.

You may not qualify if:

• Participation in clinical trials in the 12 months preceding the survey;
• Body weight \> 100 kg;
• Presence of iron deficiency anemia;
• Presence of pulmonary, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems diseases;
• Acute disease in the period of 07 days before the beginning of the practical phase (administration of the drug) of the study;
• Chronic administration of medications for hypertension, diabetes or any other disease that requires continuous use of any drug;
• Hormone therapy in the period of 02 months preceding the beginning of the practical phase (administration of the drug) of the study;
• Administration of any drug in the 02 weeks prior to the start of the practical period of the study;
• Clinical history of autoimmune or hereditary anemia;
• Clinical history of chronic bleeding;
• Clinical history of acute bleeding in the 30 days preceding the beginning of practical phase of the study (administration of the drug);
• Clinical history of allergy of biological products derived from mammalian albumin or any component of the formulation;
• Current or previous history (less than 12 months) of illicit drug abuse and / or tobacco and / or alcohol or having consumed alcohol within 48 hours prior to the practical study periods (administration of the drug);
• Prior therapies with erythropoietin;
• Albumin below 3.5 g/dL or higher than 4.8 g/dL;

Sponsors & Collaborators

• Azidus Brasil: lead

Study Sites (1)

LAL Clinica

Valinhos, São Paulo, 13276-245, Brazil

Location

MeSH Terms

Interventions

Epoetin Alfa

Intervention Hierarchy (Ancestors)

Erythropoietin; Colony-Stimulating Factors; Glycoproteins; Glycoconjugates; Carbohydrates; Hematopoietic Cell Growth Factors; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 26, 2012
• First Posted: September 14, 2012
• Study Start: February 28, 2013
• Primary Completion: October 31, 2013
• Study Completion: October 31, 2013
• Last Updated: October 28, 2022

Record last verified: 2022-10

Locations

BR (1)